Event Gaps: Claude Opus 5.5's picks for 2026-11-02
Claude Opus 5.5 picked IDXX, MRVL, PLTR, FN, CHKP for a 1-day horizon. Intraday alpha vs SPY: +3.95%. Picks with positive alpha: 80%.
| Experiment | Event Gaps |
|---|---|
| Model | Claude Opus 5.5 |
| Prompt version | event-gap-v13 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-11-02 |
| Measured to | 2026-11-03 |
| Benchmark | SPY |
| Status | Settled |
| Intraday alpha vs SPY | +3.95% |
| Picks with positive alpha | 80% |
| Benchmark return | -1.10% |
The picks
| Rank | Symbol | Gap direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | IDXX | +4.85% | +4.85% | 58% | +5.95% | Yes | |
| 2 | MRVL | -8.37% | +8.37% | 53% | +9.46% | Yes | |
| 3 | PLTR | -9.31% | -9.31% | 52% | -8.21% | No | |
| 4 | FN | +8.22% | +8.22% | 51% | +9.32% | Yes | |
| 5 | CHKP | -2.13% | +2.13% | 51% | +3.23% | Yes |
The model's market view
U.S. stocks opened higher on Nov 2, 2026 (S&P 500 about +0.6% to +0.9% mid-morning). They are rebounding from a late-October AI-capex selloff as oil fell more than 6% on reports of U.S.-Iran diplomacy. The window covers the U.S. midterm election on Nov 3 and a heavy after-close earnings slate tonight (Apple, Palantir, Fabrinet, ON Semiconductor, Vertex, Diamondback), so dispersion should be high. Picks combine post-earnings drift on today's confirmed reactions (IDXX up, CHKP down), acquirer pressure on an all-stock megadeal (MRVL down), and two after-close earnings events where expectations look reset (PLTR, FN up). Quotes are mid-morning news or delayed snapshots near the window start; partial-session OHLC could not be verified. Confidence is modest throughout.
Why each pick
IDXX
THESIS (up): IDEXX reported Q3 2026 before the open on Nov 2 (observed fact): revenue $1.214B vs $1.191B consensus, GAAP EPS $4.01 vs ~$3.71 (adjusted $3.96 vs $3.72 per Investing.com), operating margin up, >1,900 inVue Dx placements, and FY26 guidance raised to revenue $4.74-4.77B (consensus ~$4.72B) and EPS $14.96-15.16. This is a fundamental upgrade to earnings expectations, not just sentiment. My inference is that a beat-and-raise large-cap gap of this size tends to see positive post-earnings drift as analysts lift estimates/targets over the next session, so I forecast modest further upside from the current quote.
COUNTER-EVIDENCE: ChartMill notes revenue was essentially in line and the raised guide came with a lower margin outlook; the stock already moved ~+18-20% intraday, so most of the news is likely priced, and a one-day 20% gap in a ~38x P/E name invites profit-taking (emotional continuation risk cuts both ways). Election day (Nov 3) adds macro noise.
COMPLETED DAILY OHLCV (US Eastern regular sessions, split-adjusted; closes for Oct 27-29 back-computed from StockScan daily % changes anchored to the Oct 30 close and cross-checked against StockAnalysis Oct 26 close 570.21 and Oct 5 close 527.07; opens for Oct 27-29 not shown by source = null; Oct 26 bar from StockAnalysis): 2026-10-26 O 564.23 H 571.75 L 557.94 C 570.21 V 531841; 2026-10-27 O null H 567.55 L 559.03 C 561.23 V 488986; 2026-10-28 O null H 567.77 L 555.21 C 562.92 V 351840; 2026-10-29 O null H 576.17 L 568.01 C 575.98 V 479539; 2026-10-30 O 583.75 H 586.0 L 540.61 C 551.21 V 1174194. return_5d_pct = -1.64 (551.21 vs Oct 23 close 560.38). high_20d = 586.00, low_20d = 501.17, avg_volume_20d = 562,192 shares (Oct 5-Oct 30). History sources: https://stockscan.io/stocks/IDXX/price-history and https://stockanalysis.com/stocks/idxx/history
PRICE ACTION: Oct 30 opened 583.75, reversed to close 551.21 near the day low on ~2.1x average volume (pre-earnings de-risking, -4.3%). Today's gap reclaimed and exceeded the entire 20-session range (prior high 586.00), a breakout on event news rather than an extension of a prior run.
INTRADAY: latest_price 661.77 USD (Benzinga, regular session, +20.1%; exact quote_time null, published Monday morning, freshness not verifiable, likely delayed). StockTitan separately reported +18.18% at 10:00 a.m. ET. Pre-event price = Oct 30 close 551.21 (https://stockscan.io/stocks/IDXX/price-history); observed event-to-quote move = +20.06%. PARTIAL SESSION open/high/low/cumulative volume: null (not verifiable); relative intraday volume cannot be established. The quote is close to the 15:35 UTC window start; I cannot verify the elapsed-window move, so the forecast is from the current quote.
FORECAST: +2% over the remaining window (continuation). INVALIDATION: a regular-session trade back below the Oct 30 high of $586.00 (gap failure), or analyst downgrades on valuation in the next session.
MRVL
THESIS (down): OBSERVED: On Nov 2 Marvell signed a definitive all-stock agreement to buy Lumentum at a fixed 4.500 MRVL shares per LITE share (implied ~$1,132/LITE share, ~23.9% premium to the Oct 28 unaffected close, ~$115B EV); Marvell holders will own ~67% post-close, the deal is guided accretive to non-GAAP EPS in year one, and closing is expected in 1H 2028. This confirms the dilution the market feared after the Oct 28 Bloomberg leak (MRVL -13.24% Oct 29, -10.05% Oct 30). My inference: a fixed-ratio stock deal invites merger-arbitrage shorting of the acquirer against long LITE, and the very long (1H 2028) close with US/China regulatory review keeps an overhang, so selling pressure is likely to persist through the next session. This is mainly a change in share count/valuation and sentiment, not in near-term business fundamentals.
COUNTER-EVIDENCE: The stock is already ~25% below its Oct 28 close and at the bottom of its 20-session range; Benzinga cites an average price target of ~$322, ~71% above the premarket price; some outlets (TheStreet) showed MRVL briefly higher early, so sell-the-news exhaustion and an oversold bounce are real risks.
COMPLETED DAILY OHLCV (US Eastern regular sessions, split-adjusted, StockAnalysis): 2026-10-26 O 229.02 H 238.58 L 223.69 C 233.78 V 14543630; 2026-10-27 O 237.05 H 245.87 L 235.23 C 243.57 V 15452802; 2026-10-28 O 247.45 H 253.66 L 246.22 C 251.65 V 16342282; 2026-10-29 O 223.0 H 225.68 L 214.56 C 218.34 V 42028024; 2026-10-30 O 205.78 H 207.61 L 190.15 C 196.4 V 43194560. return_5d_pct = -14.05 (196.40 vs Oct 23 close 228.51). high_20d = 301.27, low_20d = 190.15, avg_volume_20d = 23,001,642 shares. History source: https://stockanalysis.com/stocks/mrvl/history/
PRICE ACTION: Two gap-down sessions on ~1.8x average volume; Oct 30 closed in the lower third of its range at a new 20-session low, i.e. a breakdown with no reversal candle yet. High volume could signal capitulation, which is the main reversal risk.
INTRADAY: latest_price 187.39 USD (Benzinga Pro via Benzinga, early Monday regular session, -4.6%); quote_time null (freshness not verifiable). Yahoo Finance showed MRVL -4.43% at 9:56 a.m. ET. Pre-event price = Oct 30 close 196.40; observed announcement-to-quote move = -4.59% (vs the Oct 28 unaffected close 251.65 the move is -25.5%). PARTIAL SESSION OHLC/volume: null; relative intraday volume cannot be established. Elapsed-window move since 15:35 UTC not verifiable.
FORECAST: -3% over the remaining window. INVALIDATION: a regular-session reclaim of the Oct 30 close $196.40, or a broad analyst-upgrade wave defending the deal.
PLTR
THESIS (up): SCHEDULED, NOT YET OCCURRED: Palantir reports Q3 2026 after the close on Nov 2. Benzinga lists consensus EPS $0.36 and revenue $2.00B, while the company itself guided Q3 revenue to $2.160-2.164B (the consensus figures conflict across sources, so the true bar is uncertain). Palantir has beaten EPS estimates five quarters running per Benzinga, with revenue surprises of ~5-8% in each of the last four quarters, and raised FY26 revenue guidance to $8.150-8.158B last quarter. My inference: another beat with a FY raise is the base case, and the stock enters the print after a -6.3% Oct 30 drop to a 20-session low, so positioning is less stretched than mid-October. Options imply roughly +/-12% (Earnings Watcher). Anticipation today is flat (+0.29% at 10:08 ET); the main move comes after the release, inside the window.
COUNTER-EVIDENCE: Extreme valuation (24/7 Wall St. cites ~82x sales and a 35% bear-case downside); the Q1 2026 print fell 6.93% despite an 18% beat; the late-October AI-capex selloff could make investors sell any guide that is merely in line. This is a high-variance call close to a coin flip.
COMPLETED DAILY OHLCV (US Eastern regular sessions, split-adjusted, TECHi/Yahoo feed): 2026-10-26 O 197.9 H 200.05 L 192.91 C 198.84 V 16380400; 2026-10-27 O 198.12 H 201.83 L 196.79 C 198.73 V 19907300; 2026-10-28 O 197.01 H 198.74 L 193.13 C 196.81 V 20821300; 2026-10-29 O 198.37 H 198.51 L 190.36 C 196.42 V 20102900; 2026-10-30 O 193.63 H 193.92 L 180.81 C 184.11 V 27007300. return_5d_pct = -6.42 (184.11 vs Oct 23 close 196.75). high_20d = 212.94, low_20d = 180.81, avg_volume_20d = 23,053,640 shares. History source: https://www.techi.com/quote/PLTR/historical/
PRICE ACTION: Range-bound $192-202 for a week, then Oct 30 broke down on ~1.2x average volume and closed near the low (bearish into the print). The 20-session high 212.94 (Oct 12) is the upside reference.
INTRADAY: latest_price 184.65 USD, quote_time 2026-11-02T10:08:00-05:00, TECHi (may be delayed; regular session), +0.29% vs prior close. No event has occurred, so the observed event reaction = null. PARTIAL SESSION OHLC/volume: null; relative intraday volume cannot be established. Elapsed-window move since 15:35 UTC not verifiable.
FORECAST: +6% over the remaining window. INVALIDATION: Q4 revenue guidance below the Street, or a post-release trade below the Oct 30 low of $180.81.
FN
THESIS (up): SCHEDULED, NOT YET OCCURRED: Fabrinet reports fiscal Q1 2027 after the close on Nov 2 (conference call 5 p.m. ET per Yahoo Finance). Last quarter it guided revenue to $1.375-1.425B and non-GAAP EPS to $4.10-4.25 (~43% YoY growth at midpoint); consensus is cited at ~$1.4B revenue and $3.88 EPS (GAAP basis per Earnings Whispers). The stock fell ~33% from the Oct 9 close (486.28) to 327.29 on sentiment, not company disclosures (Quiver: no company-specific negative announcement; Oct 30 drop linked to Amazon cash-burn concerns hitting AI optics), so expectations have reset sharply. Fundamental evidence from customers is strong: Lumentum reported revenue up ~136% to $1.26B on Nov 2, and Northland calls FN a 'major' buying opportunity after positive data points from Lumentum and Ciena. My inference: a beat-and-guide against a de-rated base (~25x trailing P/E) favors an upside move. Anticipation today is mildly positive.
COUNTER-EVIDENCE: FN fell after 5 of its last 6 reports, including -19.4% on Aug 18 despite a beat (ChartRow); Yahoo flags slowing NVIDIA-related volumes, customer concentration, margin pressure and capex as risks; options imply ~14-19%, so the direction is highly uncertain.
COMPLETED DAILY OHLCV (US Eastern regular sessions, split-adjusted; closes for Oct 26-29 back-computed from StockScan daily % changes anchored to the Oct 30 close 327.29 and cross-checked against Oct 23 close 314.94 and Oct 16 close 363.51; Oct 30 OHLC from StockScan chart/Massive; Oct 26 open from StockAnalysis; other opens null): 2026-10-26 O 318.67 H 335.53 L 312.73 C 325.21 V 688040; 2026-10-27 O null H 345.7 L 325.05 C 343.19 V 765528; 2026-10-28 O null H 375.86 L 346.0 C 367.28 V 1335469; 2026-10-29 O null H 366.65 L 348.28 C 348.66 V 1278964; 2026-10-30 O 323.45 H 338.19 L 316.78 C 327.29 V 944852. return_5d_pct = +3.93 (327.29 vs Oct 23 close ~314.91). high_20d = 515.00, low_20d = 305.63, avg_volume_20d = 980,595 shares. History source: https://stockscan.io/stocks/FN/price-history
PRICE ACTION: After a 52-week low of 305.63 on Oct 23, FN bounced ~19% intraday to 375.86 on Oct 28 on above-average volume, then gave back ~13% over two sessions; Oct 30 closed mid-range. This is a base attempt near the lows, not a breakout, and the stock is far below the 20-session high.
INTRADAY: latest_price 337.00 USD (Stocktwits, +2.97% vs the 327.29 prior close; quote_time null, live/delayed status not verifiable). No event has occurred, so the observed event reaction = null; today's move is anticipation only. PARTIAL SESSION OHLC/volume: null; relative intraday volume cannot be established. Elapsed-window move since 15:35 UTC not verifiable.
FORECAST: +8% over the remaining window. INVALIDATION: fiscal Q2 revenue guidance below ~$1.4B, or a post-release trade below the 20-session low of $305.63.
CHKP
THESIS (down): OBSERVED: Check Point reported Q3 2026 before the open on Nov 2: revenue $669.8M, down 1% YoY and below the ~$672M consensus; adjusted EPS $2.49 roughly in line; Q4 revenue guide $720-770M (midpoint flat YoY); the CEO said revenue likely troughed but the recovery is 'taking longer than anticipated'. Positives: security subscriptions +11%, RPO $2.5B (+5%), and $325M of buybacks. This is a modest negative revision to growth expectations. The stock had run ~+21% from the Oct 5 close (~129.6) to the Oct 26 high 162.44 into the print, so my inference is that pre-earnings positioning keeps unwinding and the gap down extends over the next session.
COUNTER-EVIDENCE: The stock opened weak (premarket as low as about -10.6% per Globes) but recovered to -3.87% at $146.22 per Benzinga, which shows dip-buying; the company held a 'trough' narrative with Q4 improvement expected; heavy buybacks and a low P/E (~15x) support the price. This is a low-conviction call.
COMPLETED DAILY OHLCV (US Eastern regular sessions, split-adjusted; closes back-computed from StockScan daily % changes anchored to the Oct 30 close 152.11 and cross-checked against the Investing.com Oct 12 close 134.32 and Oct 5 close 129.58; Oct 30 open from the StockScan chart; other opens not shown = null): 2026-10-26 O null H 162.44 L 158.2 C 159.64 V 1613739; 2026-10-27 O null H 160.75 L 157.73 C 159.85 V 1292621; 2026-10-28 O null H 159.56 L 154.57 C 155.23 V 1788143; 2026-10-29 O null H 154.2 L 148.0 C 153.51 V 2795186; 2026-10-30 O 155.0 H 155.1 L 148.01 C 152.11 V 2492041. return_5d_pct = -4.36 (152.11 vs Oct 23 close ~159.04). high_20d = 162.44, low_20d = 128.50, avg_volume_20d = 1,385,550 shares. History source: https://stockscan.io/stocks/CHKP/price-history
PRICE ACTION: Lower highs from Oct 26 (162.44) and two sessions on ~2x average volume (Oct 29-30) with closes in the middle of their ranges show distribution before the print; today's quote breaks below the Oct 29-30 lows (~148).
INTRADAY: latest_price 146.22 USD (Benzinga Pro via Benzinga, regular session, -3.87%; quote_time null, freshness not verifiable). Pre-event price = Oct 30 close 152.11; observed event-to-quote move = -3.87%. PARTIAL SESSION OHLC/volume: null; relative intraday volume cannot be established. Elapsed-window move since 15:35 UTC not verifiable.
FORECAST: -2% over the remaining window. INVALIDATION: a regular-session reclaim of the Oct 30 close of $152.11 (full gap fill), or analyst upgrades on the 'trough' call.
Other models on the same run
| Model | Picks | Intraday alpha vs SPY | Picks with positive alpha |
|---|---|---|---|
| Claude Sonnet 5.5 | PLTR, ON, UPST, SHOP, FN | +7.19% | 80% |
| GPT-6 | PLTR, SHOP, ON, VRTX, AAPL | -0.32% | 40% |
| Muse Spark 1.1 | PLTR, AAPL, AMD, SHOP, PFE | -3.87% | 20% |
| GPT-6.1 Sol | INTC, PLTR, VRTX, AAPL, MAR | -0.49% | 40% |
| Gemini 3 Pro | PLTR, AAPL, AMD, SMCI, VRTX | -0.86% | 40% |
| Grok 4.7 | PLTR, ON, AMD, MRVL, AAPL | -0.73% | 20% |
Written up on ForecastNest Insights: Event Gaps: Claude Opus 5.5's picks for 2026-11-02.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.